Saeed Salehin Akhand
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
38
Citations
458
Est. group size
~1
Recurring co-author estimate
Active years
13
Publishing since 2013
This researcher's work focuses on cancer biology, particularly how tumors develop drug resistance and how the immune system can be harnessed to fight cancer. Recent projects include studying engineered immune cell therapies (NK and T cell engagers) that target specific cancer proteins, and earlier work examined how a signaling pathway called FGFR helps breast cancer cells survive treatment and spread. The research spans laboratory studies of cancer cell mechanisms to translational work on developing new cancer immunotherapies.
Publication output was modest and variable through most of the decade but showed a sharp increase in 2023, followed by continued activity in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- ABBV-303 Is an NK-cell Engager Specific for c-Met–Expressing Tumors
Cancer Research · 2025
- Abstract 3395: Investigating clinical features and molecular mechanisms of long-term response and acquired resistance to immunotherapy in non-small cell lung cancer by applying real-world-data
Cancer Research · 2025
- Abstract ND01: ABBV-303: A novel NK and CD8 T cell engager specific for c-Met-expressing tumors
Cancer Research · 2024
- 1282 ABBV-303 engages and redirects NK and CD8 T cells to lyse c-Met expressing tumor cells
Regular and Young Investigator Award Abstracts · 2024
- Data from Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade
2023
- Supplementary Figures from Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade
2023
- Supplementary Figures from Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade
2023
- Data from Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade
2023
- Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication
Molecular Therapy — Methods & Clinical Development · 2022
- Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy
npj Breast Cancer · 2021
- PHARMACOLOGICAL TARGETING OF FGFR SIGNALING TO INHIBIT BREAST CANCER RECURRENCE AND METASTASIS
Figshare · 2020
- Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy
bioRxiv (Cold Spring Harbor Laboratory) · 2019
- Abstract 2850: FGFR signaling facilitates recurrence of minimal residual disease post trastuzumab emtansine treatment in breast cancer
Cancer Research · 2018
- Targeting FGFR for the Treatment of Breast Cancer
Resistance to targeted anti-cancer therapeutics · 2017
- FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition
Oncotarget · 2016
- Cancer Research×8
- Oncogene×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
- Journal of the American Chemical Society×1
- Molecular Therapy — Methods & Clinical Development×1
- Ing‐Ming Chiu
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Eric Samorodnitsky
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Aneesha Kulkarni
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Amy Smith
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Julie W. Reeser
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile